Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01971164 · ClinicalTrials.gov registry record · Phase 1
Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease
A Phase 1 study, sponsored by Akros Pharma.
- Completed
- Registry status
- Phase 1
- Development phase
- 29
- Enrollment target
NCT01971164 is a Phase 1 study that has completed, run by Akros Pharma. The registered enrollment target is 29 participants.
The verdict
NCT01971164, a Phase 1 study, has completed, sponsored by Akros Pharma.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 29 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of sequential ascending doses of JTZ-951 administered for 15 days in anemic subjects with end-stage renal disease (ESRD) receiving hemodialysis.
Interventions
- DRUG Placebo
- DRUG JTZ-951
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 29 participants |
| Start Date | 2013-05 |
| Est. Completion | 2014-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01971164
The ClinicalTrials.gov registry entry for NCT01971164 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 29 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Akros Pharma, which has 18 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01971164 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01971164 about?
NCT01971164 is a clinical study titled "Safety, Tolerability, PK & PD Study of JTZ-951 in Anemic Subjects With End-stage Renal Disease". The purpose of this study is to determine the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of sequential ascending doses of JTZ-951 administered for 15 days in anemic subjects with end-stage renal disease (ESRD) receiving hemodialysis.
What is the current status of trial NCT01971164?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 29 participants. The study started on 2013-05. Estimated completion is 2014-07.
What interventions are being tested in trial NCT01971164?
The interventions under investigation include: Placebo (DRUG), JTZ-951 (DRUG).
Who is sponsoring clinical trial NCT01971164?
This trial is sponsored by Akros Pharma, which has 18 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.